Download presentation

Presentation is loading. Please wait.

Published byRuth Milk Modified about 1 year ago

1
1 Metabolomics a Promising ‘omics Science By Susan Simmons University of North Carolina Wilmington

2
2 Collaborators Dr. David Banks, Duke Dr. Chris Beecher, University of Michigan Dr. Xiaodong Lin, University of Cincinnati Dr. Young Truong, UNC Dr. Jackie Hughes-Oliver, NC State Dr. Stanley Young, NISS Dr. Ann Stapleton, UNCW Biology Dr. Robert Simmons, MD

3
3 What is Metabolomics? The word metabolome was first used less than a decade ago (1998) and referred to all low molecular mass compounds synthesized and modified by a living cell or organism (Villas- Boas, 2007) The complete human metabolome consists of endogenous (~1800) and exogenous metabolites (MANY!!) Human Metabolome Project

4
4

5
5 Fluorene degradation - Reference pathway (www.genome.jp/KEGG Kyoto Encyclopedia of Genes and Genomes)www.genome.jp/KEGG

6
6 Mass Distribution of Compounds in the Human Metabolome Metabolome natively biosynthesized monomeric Complex metabolites Xenobiome

7
7 History of Metabolomics Machinery to detect metabolites have existed since the late 1960’s First paper appeared in 1971 (Robinson and Pauling) First paper involving “metabolomics” came about in the late 1990’s

8
8 Why Metabolomics can be promising Easy to use screening for disease Assist in identifying gene function Drug discovery Assessment of toxicity (especially liver toxicity) in new drugs. Nutrigenomics and diet strategies

9
9 Genomics,Proteomics and Metabolomics

10
10 The emerging science of Metabolomics

11
11 Metabolomics DNA RNA Protein Biochemicals (Metabolites) Genomics – 25,000 Genes Transcriptomics – 100,000 Transcripts Metabolomics – 1,800 Compounds Proteomics – 1,000,000 Proteins

12
12 Biochemical Profile Map to Metabolic Pathways Biochemical Profile

13
13 Data Collection and Measurement Issues To obtain data, a tissue sample is taken from a patient. Then: The sample is prepped and put onto wells on a silicon plate. Each well’s aliquot is subjected to gas and/or liquid chromatography. After separation, the sample goes to a mass spectrometer.

14
14 MS platforms Sample Preparation GC MS/ei Data Set Metabolyzer LC MS /+ MS /- Data Extraction -peak identification -peak alignment -peak deconvolution Chemical Identification - reference databases -ion spectra -grouping related ions -compound id Quantitation Quality Control Data Reduction PreparationAnalysisInformatics LIMS No Interpretation Interface

15
15 Data Collection and Measurement Issues The sample prep involves stabilizing the sample, adding spiked-in calibrants, and creating multiple aliquots (some are frozen) for QC purposes. This is roboticized. Sources of error in this step include: within-subject variation within-tissue variation contamination by cleaning solvents calibrant uncertainty evaporation of volatiles.

16
16 Data Collection and Measurement Issues The result of this is a set of m/z ratios and timestamps for each ion, which can be viewed as a 2-D histogram in the m/z x time plane. One now estimates the amount of each metabolite. This entails normalization, which also introduces error. The caveats pointed out in Baggerley et al. (Proteomics, 2003) apply.

17
17 Data Collection and Measurement Issues Baseline correction Alignment Estimating quantity of specific metabolites.

18
18

19
19 Data Collection and Measurement Issues Let z be the vector of raw data, and let x be the estimates. Then the measurement equation is: G(z) = x = µ + ε where µ is the vector of unknown true values and ε is decomposable into separate components. For metabolite i, the estimate X i is: g i (z) = lnΣ w ij ∫∫sm(z) – c(m,t)dm dt.

20
20 Data Collection and Measurement Issues The law of propagation of error (this is essentially the delta method) says that the variance in X is about Σ n i=1 (∂g /∂ z i ) 2 Var[z i ] + Σ i≠k 2 (∂g/∂z i )(∂g/∂z k ) Cov[z i, z k ] The weights depend upon the values of the spiked in calibrants, so this gets complicated.

21
21 Data Collection and Measurement Issues Cross-platform experiments are also crucial for medical use. This leads to key comparison designs. Here the same sample (or aliquots of a standard solution or sample) are sent to multiple labs. Each lab produces its spectrogram. It is impossible to decide which lab is best, but one can estimate how to adjust for interlab differences.

22
22 Data Collection and Measurement Issues The Mandel bundle-of-lines model is what we suggest for interlaboratory comparisons. This assumes: X ik = α i + β i θ k + ε ik where X ik is the estimate at lab i for metabolite k, θ k is the unknown true quantity of metabolite k, and ε ik ~ N(0,σ ik 2 ).

23
23 Data Collection and Measurement Issues To solve the equations given values from the labs, one must impose constraints. A Bayesian can put priors on the laboratory coefficients and the error variance. Metabolomics needs a multivariate version, with models for the rates at which compounds volatilize.

24
24

25
25

26 26 Statistical issues Many missing values!!! Outliers Distribution of metabolites are not normally distributed n

27
27 Statistical Issues PCA or ICA Partial Least Squares Clustering Random Forest, SVM rSVD

28
28 Statistical issues Dealing with missing values Replacing missing values by 0’s is not necessarily a good idea. Not truly 0. Minimum, half-min, uniform(0, minimum) Random forest imputation Observing conditional distribution (Dr. Young Truong at UNC)

29
29 Statistical Issues Prediction and Classification Partial least squares Random Forest SVM Neural networks

30
30 Statistical Issues Identifying relationships MDS Clustering rSVD (PowerMV from NISS)

31
31 ALS metabolomic data set We had abundance data on 317 metabolites from 63 subjects. Of these, 32 were healthy, 22 had ALS but were not on medication, and 9 had ALS and were taking medication. The goal was to classify the two ALS groups and the healthy group. Here p>n. Also, some abundances were below detectability.

32
32 ALS metabolomic data set Using the Breiman-Cutler code for Random Forests, the out-of-bag error rate was 7.94%; 29 of the ALS patients and 29 of the healthy patients were correctly classified. 20 of the 317 metabolites were important in the classification, and three were dominant. RF can detect outliers via proximity scores. There were four such.

33
33 ALS Metabolomic data set Several support vector machine approaches were tried on this data: Linear SVM Polynomial SVM Gaussian SVM L 1 SVM (Bradley and Mangasarian, 1998) SCAD SVM (Fan and Li, 2000) The SCAD SVM had the best loo error rate, 14.3%.

34
34 ALS Metabolomic data set Robust SVD (Liu et al., 2003) is used to simultaneously cluster patients (rows) and metabolites (columns). Given the patient by metabolite matrix X, one writes X ik = r i c k + ε ik where r i and c k are row and column effects. Then one can sort the array by the effect magnitudes.

35
35 ALS metabolomic data set To do a rSVD use alternating L 1 regression, without an intercept, to estimate the row and column effects. First fit the row effect as a function of the column effect, and then reverse. Robustness stems from not using OLS. Doing similar work on the residuals gives the second singular value solution.

36
36

37
37 NCI data set NCI 60 cell lines 9 cancer types: breast, CNS, colon, melanoma, renal, leukemia, prostate, ovarian, lung GC-LS Melanoma vs CNS (8 cell lines for melanoma and 6 cell lines for CNS)

38
38 Variable Importance using RF

39
39 Component 1 versus 2

40
40 Useful websites Deconvolution of peaks, software AMDIS (http://chemdata.nist.gov/massspc/amdis; NIST, Gaithersburg, USA)http://chemdata.nist.gov/massspc/amdis Human Metabolome database (www.hmdb.ca)www.hmdb.ca KEGG (www.genome.jp/kegg)www.genome.jp/kegg Many, many others

41
41 Concluding Remarks Many interesting statistical issues still need to be addressed. Measurement issues and interlaboratory differences need to be properly addressed. Statistical issues in analyzing metabolomic data still remain an interesting challenge. Metabolomics is an important part in understanding systems biology.

Similar presentations

© 2016 SlidePlayer.com Inc.

All rights reserved.

Ads by Google